PDAC with an impaired TGF-β-SMAD4 signalling pathway per se may modulate the fibrotic response and mechanophenotype [121], indicating that molecular alterations in tumours not only control PDAC progression but also reprogram the metabolic phenotypes of cells in the TME. The gene discussed is SMAD4; the disease is neoplasm.